Kornimate/medical-research-clean huggingface dataset:
individual neuromodulation for pds

Conditions: Neuromodulation; Parkinsonian Syndromes; Transcranial Magnetic Stimulation; Transcranial Direct Current Stimulation

Summary: parkinsonian syndromes (pds) with predominant motor dysfunction include progressive supranuclear palsy (psp), multiple system atrophy (msa) and corticobasal degeneration (cbd). current treatment options for pds are extremely limited due to the less understanding of disease pathophysiology and lack of therapeutic targets. combining the results of previous studies and our group's previous research, sixty qualified pds patients would be enrolled to conduct a prospective single-center randomized sham controlled clinical trial to verify the new therapeutic options that can improve symptoms and effectively slow the progression of the disease.


Eligibility criteria:
inclusion criteria: * compliance with the mds revised clinical diagnostic criteria for parkinsonian syndrome (2015 edition) * aged \>40 years and \<80 years, regardless of gender. * patients were relatively stable during the study period and remained stable on medication * good compliance, written informed consent, and consent for nibs long-term intervention treatment exclusion criteria: * patients with severe neuropsychiatric disorders or a previous history of severe neurologic conditions (e.g., epilepsy, cerebrovascular accident, etc.) or traumatic brain injury or brain surgery * inability to complete the questionnaire independently * previous treatment with dbs or scs; tms or tdcs within 6 months * severe physical illness and any physical condition that can precipitate epilepsy or intracranial hypertension, including cardiovascular and respiratory diseases * installation of intracranial stents, pacemakers, coronary stents, cochlear implants, and other human implantable materials * is currently taking other investigational drugs or is participating in other clinical trials * any other condition that the investigator believes makes him or her unsuitable for participation in this study.
evaluation of the food allergy mastery program

Conditions: Food Allergy in Children

Summary: the proposed research project will evaluate a novel behavioral intervention that promotes early adolescent food allergy self-management and adjustment through 1) food allergy education, 2) problem-solving, communication, assertiveness, and anxiety management skill building, and 3) peer support.

the proposed research project will evaluate a novel behavioral intervention that promotes early adolescent food allergy self-management and adjustment through 1) food allergy education, 2) problem-solving, communication, assertiveness, and anxiety management skill building, and 3) peer support. the food allergy mastery (fam) program is a 6-session food allergy self-management program that will be delivered to early adolescents with food allergy, a high-risk population that is growing in size, and a primary caregiver by a trained interventionist. the specific aims are: 1) to evaluate the intervention's impact on food allergy knowledge and self-management skills, 2) to determine the intervention's impact on food allergy self-management behavior and psychosocial functioning and healthcare utilization, and as an exploratory aim 3) to determine if early adolescents' race/ethnicity moderates response to treatment, including food allergy knowledge, skills, self-management behavior, psychosocial functioning, and healthcare utilization. the study has the potential to positively impact the health care utilization of youth with food allergy by evaluating a scalable behavioral intervention for adolescents and their caregivers. the intervention will equip youth with food allergy knowledge and self-management skills by bolstering their food allergy-related knowledge and problem-solving, social skills, and social support and attenuating food allergy anxiety. successful development and implementation of the fam program that promotes the attainment of integration of food allergy into daily life has the potential to decrease health care utilization reducing emergency visits and improve food allergy-related quality of life.

Eligibility criteria:
inclusion criteria: 1. age 10-14 years 2. physician diagnosis (i.e., history of a reaction to the food and/or recent positive skin prick test or ige-specific testing) of at least 1 of the 9 most common ige-mediated food allergies (peanut, tree nut, cow's milk, egg, soy, wheat, shellfish, fish, sesame) for ≥1 year, with accompanying allergen avoidance prescribed by an allergist 3. english fluency 4. access to a device with internet access 5. either a food allergy knowledge score of \<80% correct on the food allergy knowledge test (fakt) or a food allergy impact score of ≥3 on the food allergy independent measure (faim). exclusion criteria: 1. diagnosis of a non-ige-mediated food allergy or food intolerance, a non-atopic chronic illness or pervasive developmental disorder/cognitive limitation 2. current participation in psychotherapy with a therapist with food allergy expertise

Keywords: food allergy knowledge management adolescents caregivers social support
a study to evaluate treatment satisfaction with erenumab in participants with migraine

Conditions: Migraine

Summary: the main purpose of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * participant has provided informed consent * history of migraine (with or without aura) for ≥ 12 months before screening * ≥ 4 migraine days per month on average across the 3 months prior to screening * treatment with 1 oral migraine preventive medication and/or concomitant use of onabotulinumtoxina injections for migraine prevention. * participant reports to their provider intolerance or insufficient response with their current preventative treatment exclusion criteria: * history of cluster headache or hemiplegic migraine headache * unable to differentiate migraine from other headaches * evidence of substance-related disorders * active chronic pain syndromes (eg, fibromyalgia and chronic pelvic pain) * no therapeutic response with \> 3 migraine preventive medication categories * used a prohibited medication, device, or procedure * other clinically significant disorder, condition, or disease

Keywords: migraine chronic migraine episodic migraine erenumab
quality of life of periodontitis patients visiting supportive periodontal therapy

Conditions: Quality of Life; Periodontal Diseases

Summary: the present prospective study aims to assess the qol of periodontitis patients during supportive treatment and to relate it to periodontal health (clinical and radiographic data) and treatment stability. follow-ups after the first cross-sectional assessment are planned after approximately 2.5, 5, 7.5, and 10 years.


Eligibility criteria:
inclusion criteria: * all patients returning for supportive therapy on a regular basis after active periodontal treatment will be asked for participation if they are in supportive therapy for at least 1 year.
quantitative mr biomarkers for sarcoma treatment

Conditions: Soft Tissue Tumors

Summary: to determine if mri imaging can be used to accurately determine if a sarcoma is responding to the type of chemotherapy being used.

the purpose of this study is to determine if mri imaging can be used to accurately determine if a sarcoma is responding to the type of chemotherapy being used or if it is ineffective early on in the treatment; instead of finding this out 2-3 months later. if it is determined that mri can accurately diagnose tumor response, medications can be switched early on potentially improv8ing the patients'chances of recovery.

Eligibility criteria:
inclusion criteria: 1. biopsy proven primary bone or soft tissue tumor 2. no previous treatment for this malignancy 3. will be given chemotherapy before having surgery or radiation on the tumor. 4. are able to undergo a mri examination 5. if your tumor measures at least 1/2 inch in length. exclusion criteria: 1. younger than 3 yrs. of age or need general anesthesia(sedation that puts you to sleep) to have a mri performed. 2. history of renal failure 3. are not able to have a mri performed for any reason such as you have a pacemaker or other implanted device that may malfunction or move because of the magnetic field inside the mri room and scanner. 4. have any history of an allergic reaction to gadolinium based contrast agents (a medication injected in a vein that helps create clearer mri images. -
minimizing reperfusion injury in patients with acute myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: the size of a heart attack will be decreased by the use of timed balloon inflations to open the blocked blood vessel.

the intervention of "post conditioning" at the time of reperfusion, in patients with acute myocardial infarction (ami), will attenuate the degree of ischemia-reperfusion injury, as manifested by infarct size. this intervention is hypothesized to be safe in humans.

Eligibility criteria:
inclusion criteria: * stemi * onset of symptoms within 6 hours * timi 0 to timi 1 flow in infarct related artery exclusion criteria: * collaterals to infarct related artery * previous infarct in related territory * thrombolytics * cardiogenic shock * timi 2 to timi 3 flow

Keywords: st segment elevation myocardial infarction (stemi) timed balloon inflations post conditioning
comparative effect of theipoental and propofol in ivf outcome

Conditions: Subfertility

Summary: in this study the aim is to compare the effect of the type of anaesthetic drug used during oocyte retrieval on fertilization rates of oocytes retrieved after ovarian stimulation for in-vitro fertilization.


Eligibility criteria:
inclusion criteria: * women undergoing oocyte retrieval for ivf under general anesthesia * age ≤45 years exclusion criteria: * women with a known hypersensitivity to the active substance of the investigating drugs or any of their excipients
patients with low-grade non-hodgkin's lymphoma previously treated with iodine i 131 tositumomab

Conditions: Lymphoma, Non-Hodgkin

Summary: this is a multi-center study for the long-term follow-up of surviving patients who are expected to complete or who have completed at least two years of follow-up after treatment with iodine i 131 tositumomab (bexxar) on studies cp-97-011, cp-98-025, cp-99-032, or cp-99-036. all patients will be assessed for survival and disease status, including subsequent therapy for nhl, and for long-term safety. additionally laboratory evaluations consisting of a tsh level and a complete blood cell (cbc) count with a differential and platelet count will be obtained annually. additionally, patients who remain in long-term response following iodine i 131 tositumomab treatment will be followed for response and progression.


Eligibility criteria:
inclusion criteria: * patients must have enrolled in one of the following corixa sponsored clinical trials: cp-97-011, cp-98-025, cp-99-032, or cp-99-036 and are \>2 years post treatment with iodine i 131 tositumomab. * patients must give written informed consent by signing an irb/ethics committee approved consent form prior to entry on this follow-up study. exclusion criteria: * inability to meet above referenced inclusion criteria.

Keywords: long-term follow-up bexxar iodine i 131 tositumomab low-grade lymphoma
a prospective clinical study evaluating the harvesting of micografts

Conditions: Chronic Wound

Summary: art (autologous regeneration of tissue) is a revolutionary technology for harvesting skin without the drawbacks of conventional grafting. this innovative system allows the clinician to collect hundreds of microcolumns of full-thickness skin tissue and apply them directly to the wound site. it can all be done in an outpatient setting with minimized donor site concerns.

millions of americans suffer from acute and hard-to-heal chronic wounds. the national institutes of health estimates that 3% of the u.s. population over the age of 65 has an open wound. as the population ages in concert with an increased incidence of diabetes and obesity, the problem will intensify. a recent article suggests that the financial burden of wound care is approaching 100 billion dollars. despite the gravity of the problem and the number of patients afflicted, open wounds can take weeks, months or even years to heal. the search for interventions that promote healing, reduce suffering and enhance quality of life continues as does the need to address the underlying issues that disrupt the wound healing process. countless hours are spent treating chronic wounds (diabetic ulcers, venous ulcers, pressure injuries). called the "silent epidemic," chronic wounds often result in infection, disability and sometimes amputation. crafting a treatment plan that addresses the individual needs of each wound and each patient, hinges on managing the underlying issues that can disrupt healing and increase healthcare costs. innovation in wound bed preparation and tissue regeneration bring new hope for these patients in the form of more effective wound closure, improved quality of life and reduced costs. autologous skin grafting is the gold standard for covering areas of skin loss.4 however, traditional grafting is limited by accessibility issues and donor site complications-pain, risk of infection, scarring. art (autologous regeneration of tissue) is a revolutionary technology for harvesting skin without the drawbacks of conventional grafting. this innovative system allows the clinician to collect hundreds of microcolumns of full-thickness skin tissue and apply them directly to the wound site. it can all be done in an outpatient setting with minimized donor site concerns.

Eligibility criteria:
inclusion criteria: group a (healthy individuals) 1. 18 years or older. 2. healthy participants without major diseases. group b (subjects with chronic wounds) 1. participants presenting with chronic wound(s) present for a minimum of 4 weeks (eg. diabetic foot ulcers (dfu), venous leg ulcers (vlu), pressure ulcers (pru), and other acceptable etiologies). 2. 18 years or older. exclusion criteria: 1. subject on an investigational drug or therapeutic device within 30 days of the study visit. 2. presence of a condition that pi considers will compromise the subject's ability to participate in the study. 3. known allergy to any of the dressings or their components. 4. the subject has a history of excessive bleeding. 5. the subject has a history of keloid formation.
a role for brown adipose tissue in postprandial thermogenesis?

Conditions: Obesity; Diabetes; Cardiovascular Disease

Summary: brown adipose (fat) tissue (bat) is a type of fat tissue found in certain small rodents and human babies that is capable of extremely high rates of energy burning. we now know that in adult humans it is present and also able to burn energy. in addition to increased energy expenditure during cold exposure, energy burning is also increased after consuming a meal. animal studies have shown that part of this additional energy consumption is contributed by bat. in the present study we will aim to examine whether bat activity is increased after a meal.

the purpose of this project is to measure whether bat activity (during which bat increases energy burning) increases in response to ingestion of a meal. bat is one of two types of fat, (the other being white fat), which is found in humans and other mammals. in this study we aim to further our understanding of how bat works in humans. studies in animals show that in addition to cold exposure, bat is also activated by ingestion of a meal, and to different amounts depending on the meal composition, and more importantly, total energy content. however we have only a very limited understanding of bat function in response to meals in humans. since bat function is defective in obesity, and its activity and function are impacted by diet, here we will find out whether a single high energy meal composed entirely of lipid (fat) can increase bat activity. in future these findings and those of subsequent studies may have important implications for the management of obesity and related diseases. a total of 20 people will participate in this project. participation will involve a total of 3 visits, including a screening visit, 2 experimental visits consumption of the treatment meal on one visit, and the placebo (dummy) on the other in a randomised order.

Eligibility criteria:
inclusion criteria: * males aged 19 - 35 years * unmedicated for the previous 2 months * no major illness * bmi 17-40 kg/m2 exclusion criteria: * unable to give informed consent * smokers * participant in research projects involving ionising radiation within the past 5 years, excluding dual energy x-ray absorptiometry scans conducted in prior studies * claustrophobia * fasting plasma glucose \> 6.0 mmol/l
the impact of non-alcoholic fatty pancreas disease on outcome of acute pancreatitis

Conditions: Non-Alcoholic Fatty Pancreas Disease; Acute Pancreatitis

Summary: obesity is a well-established risk factor for acute pancreatitis (ap). as for non-alcoholic fatty pancreas disease (nafpd), it is evident that it is correlated with obesity. this is apparently the first study evaluating the association between nafpd and severity of ap after taking into account several covariates.

acute pancreatitis (ap) is a common disease with a highly variable clinical course, which can range from a mild, self-limited disease to severe disease with a mortality rate of 10-20%. it is vital to distinguish severe cases early because they require more aggressive fluid resuscitation and early nutritional support. obesity is a well-established risk factor for acute pancreatitis (ap). it leads to ectopic fat accumulation in visceral organs, such as the liver, skeletal muscles, heart and pancreas. assuming that attenuation in the pancreas seen on unenhanced computed tomography (ct) scanning is inversely associated with severe outcomes in ap, we investigated the relationship between nafpd and severity of ap and the significance of pancreas attenuation for the prognosis and mortality in ap patients. the result of this study suggest that decreased pancreas attenuation and p/s ratio are strong predictors of severe pancreatitis, mortality, systemic complication.

Eligibility criteria:
inclusion criteria: 1. diagnosed with ap 2. age\>18y exclusion criteria: 1. age\<18y 2. missing data in the electronic medical record 3. prior attacks of ap 4. without spleen 5. with ambiguous pancreatic margin
microvascular and antiinflammatory effects of rivaroxaban compared to aspirin in type-2 diabetic patients with subclinical inflammation and high cardiovascular risk

Conditions: Type 2 Diabetic Patients

Summary: study to investigate microvascular and antiinflammatory effects of rivaroxaban compared to low dose aspirin in type 2 diabetic patients. especially patients with cardiovascular disease and subclinical inflammation are in the focus of interest.


Eligibility criteria:
inclusion criteria: * type 2 diabetes duration between 2 and 20 years * two or more components of metabolic syndrome: * hdl-cholesterol \< 1.0 mmol/l (in males) or \< 1.3 mmol/l (in females) * elevated triglycerides (\> 1.7 mmol/l) * elevated blood pressure (\> 130 mmhg systolic and/or \>85 mmhg diastolic or antihypertensive treatment) * elevated waist circumference (\> 102 cm in males, \> 85 cm in females) * or at least one of the following * carotid ultrasound showing an imt \> 1 mm and plaque of carotid artery or * left ventricular hypertrophy or * increased uacr in the absence of other renal diseases than diabetic nephropathy * increased hscrp (\> 2 mg/l but \ 15 ng/ml) at or within 6 months prior to screening (the historical hscrp or pai 1 value can be used only if the patient was in stable conditions regarding the concomitant diseases and statin therapy since the time point of measurement) * stable treatment with statins (if tolerated/clinically indicated) * age 40 - 75 years exclusion criteria: * major cardiovascular (cv) event with need for oral anticoagulation or platelet inhibitor therapy or acute coronary syndrome \< 12 month before study entry * sustained uncontrolled hypertension: systolic blood pressure \> 180 mmhg or diastolic blood pressure \> 100 mmhg * hypersensitivity to the active substance or to any of the excipients * active clinically significant bleeding * lesion or condition, if considered to be a significant risk for major bleeding * concomitant treatment of acute coronary syndrome (acs) with antiplatelet therapy in patients with a prior stroke or a transient ischemic attack (tia) * hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with child pugh b and c * chronic renal failure with egfr \< 15 ml/min (mdrd formula) * pregnant or breast-feeding woman and woman without adequate method of contraception.
micafungin prophylaxis during 1st induction chemotherapy for de novo acute leukemia

Conditions: Acute Leukemia

Summary: the purpose of this study is to determine whether prophylaxis with micafungin is effective in the induction chemotherapy for newly diagnosed acute leukemia patients.

medically fit patients with newly diagnosed acute leukemia received 50 mg micafungin intravenously once daily from the initiation of first induction chemotherapy to recovery of neutrophil count, suspected fungal infection, or unacceptable drug-related toxicity.

Eligibility criteria:
inclusion criteria: a. patients belong to either a-1 or a-2 a-1. patients with newly diagnosed acute myeloid leukemia who approve to get induction chemotherapy with (cytarabine plus idarubicin) or (modified fludarabine + cytarabine + idarubicin ) a-2. patients with newly diagnosed acute lymphoid leukemia who approve to get induction chemotherapy with vpdl (vincristine + prednisolone + daunorubicin + l-asparaginase), c-vpdl (cyclophosphamide + vincristine + prednisolone + daunorubicin + l-asparaginase), or (r)-hypercvad ((rituximab) + cyclophosphamide + vincristine + adriamycin + dexamethasone) b. eastern cooperative oncology group performance status score is equal to or more than 2 c. patients who voluntarily sign the agreement exclusion criteria: a. evidence of proven/probable/possible fungal infection within 30 days before induction chemotherapy b. hypersensitivity to echinocandin c. patients had other malignancy within 5 years d. previous treatment history with chemotherapy, radiation therapy, or immunosuppressive therapy. e. pregnant or breast-feeding women f. immunodeficient patients including aids g. patients with uncontrolled seizure or psychiatric disorder h. clinically significant heart disorder (myocardial infarction within 3 months or left ventricular ejection fraction \< 40%) i. interstitial lung disease j. previous organ transplantation history k. galactose intolerance l. patients who participated this study before.

Keywords: leukemia induction prophylaxis antifungal micafungin phase ii